This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| erlotinib | |
|---|---|
| Name | Erlotinib |
| Tradename | Tarceva |
| Routes of administration | Oral |
| Legal status | Prescription-only |
| Class | Tyrosine kinase inhibitor |
erlotinib is an orally administered small-molecule anticancer agent approved for treatment of certain non-small-cell lung cancer, pancreatic cancer, and investigated in multiple solid tumors. It is developed to target signaling pathways implicated in cell proliferation and survival and is prescribed within oncology practice alongside other targeted therapies and cytotoxic regimens. Major regulatory decisions by agencies such as the Food and Drug Administration and the European Medicines Agency have shaped its clinical indications and postmarketing surveillance.
Erlotinib is indicated for locally advanced or metastatic non-small-cell lung cancer after progression on first-line chemotherapy and for advanced pancreatic cancer in combination with gemcitabine. Oncology guidelines from bodies including the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the European Society for Medical Oncology define its role relative to agents like gefitinib, afatinib, osimertinib, and chemotherapy regimens such as platinum-based chemotherapy and paclitaxel. It is used in molecularly selected populations based on mutational testing performed in laboratories aligned with standards from agencies like the College of American Pathologists and the World Health Organization. Clinical trials led by cooperative groups including the Eastern Cooperative Oncology Group and the Alliance for Clinical Trials in Oncology informed its approvals and label updates.
Erlotinib inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR), blocking downstream signaling pathways such as the RAS–RAF–MEK–ERK pathway and the PI3K–AKT–mTOR pathway. The drug binds to the ATP-binding site of EGFR, preventing autophosphorylation and recruitment of adaptor proteins involved in proliferation and anti-apoptotic signaling. Resistance mechanisms characterized in research from institutions like Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center include secondary EGFR mutations (for example, T790M), activation of bypass tracks via MET amplification, and histologic transformation similar to observations in studies by Johns Hopkins University investigators.
Erlotinib is a reversible inhibitor that exhibits selectivity for EGFR compared with other receptor tyrosine kinases studied at centers including Cold Spring Harbor Laboratory and Salk Institute. Preclinical pharmacology was characterized using xenograft models from research groups at institutions such as University of California, San Francisco and Harvard Medical School, and biomarker analyses incorporated methodologies from laboratories affiliated with the Broad Institute and Wellcome Trust Sanger Institute. Comparative evaluations with agents like cetuximab, panitumumab, and small molecules such as lapatinib have delineated its position in targeted therapy paradigms developed by pharmaceutical companies including Genentech, AstraZeneca, and Bristol-Myers Squibb.
Common toxicities include dermatologic reactions such as acneiform rash, paronychia and xerosis; gastrointestinal effects including diarrhea and nausea; and laboratory abnormalities. Serious events reported in postmarketing surveillance coordinated with regulators like the Food and Drug Administration and analyzed by institutes like the European Medicines Agency include interstitial lung disease, hepatotoxicity, and rare ocular complications. Management strategies have been codified in practice statements from organizations such as the American Academy of Dermatology, the Society of Gynecologic Oncology for specific contexts, and consensus panels convened by the International Association for the Study of Lung Cancer. Drug safety signals have been monitored in pharmacovigilance databases maintained by entities like the World Health Organization's pharmacovigilance program.
Erlotinib is administered orally, with absorption affected by food and gastric pH; agents that alter intragastric acidity such as proton pump inhibitors produced by companies like AstraZeneca and Johnson & Johnson can modify exposure. Metabolism is predominantly via the cytochrome P450 enzyme CYP3A4, with contributions from CYP1A2 and CYP1A1, pathways characterized in publications from laboratories at the University of Cambridge and Imperial College London. Hepatic impairment, smoking status studied in cohorts from institutions including University of Toronto and University of California, Los Angeles, and genetic polymorphisms influence clearance and variability observed in pharmacokinetic analyses published in journals overseen by editorial boards like those of the New England Journal of Medicine and Lancet Oncology.
Because of CYP3A4 metabolism, erlotinib interacts with strong inhibitors and inducers such as ketoconazole, rifampin, and certain antiretrovirals used in protocols from centers like Beth Israel Deaconess Medical Center and St. Jude Children's Research Hospital. Concomitant use with medications affecting gastric pH, including H2 blockers and proton pump inhibitors used in gastroenterology practice at institutions like Mayo Clinic and Cleveland Clinic, alters bioavailability. Polypharmacy considerations overlap with treatment regimens described by cooperative groups such as SWOG and EORTC and require coordination with clinical pharmacists trained at programs like those at University of Michigan and University of Sydney.
Discovery and development of erlotinib occurred within pharmaceutical research programs and collaborative academic-industry partnerships, with early clinical trials run by investigators affiliated with Genentech, OSI Pharmaceuticals, and academic centers including Peter MacCallum Cancer Centre and Royal Marsden Hospital. Regulatory milestones involved submissions to the Food and Drug Administration and approvals that were reported in medical news outlets and journals such as Journal of Clinical Oncology and New England Journal of Medicine. Subsequent research programs examined combinations with cytotoxics and targeted agents in trials supported by cooperative groups like Gynecologic Oncology Group and multinational consortia coordinated by the International Agency for Research on Cancer. The drug’s development history intersects with scientific advances in genomics from the Human Genome Project and precision oncology initiatives spearheaded by institutions such as the NIH and the Wellcome Trust.
Category:Antineoplastic agents